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South East Wales Vascular Network, Royal Gwent Hospital, Newport, UKIndications for carotid endarterectomy (CEA) have evolved
as stroke services have improved. Hyperacute stroke units
are referring more patients with a signiﬁcant carotid ste-
nosis, some within hours of thrombolysis. In their meta-
analysis, Mandavia et al. pooled the evidence to date to
attempt to assess 30-day safety of urgent CEA for these
patients.1 However, care must be taken with the interpre-
tation and contextualization of these results.
The introduction and discussion of this meta-analysis
quote from NICE guidelines, ECST and NASCET, which is
misleading in this setting. NICE guidelines have no pathway
for carotid surgery after thrombolysis.2 Patients who
received thrombolysis were not included in ECST, NASCET,
or any other randomised trial of carotid intervention to
date, so results are not directly comparable with the 30-day
stroke and death rate from this analysis.
Although the headline estimate of a 5% 30-day stroke/
death rate may seem reasonable, this is not being consid-
ered in the context of outcomes after thrombolysis for
stroke. The reality is that the fate of the matched throm-
bolysed patient treated with modern best medical therapy
is unknown. There are no published subgroup analyses from
the stroke thrombolysis trials with which to compare these
results. Recurrent ischaemic stroke in the ﬁrst 7 days after
thrombolysis was actually rare (1%).3
The 30-day estimate of stroke or death after CEA in this
analysis was between 2% and 9%. This large conﬁdence
interval reﬂects the low number of events (4 strokes and 4
deaths) from which it was derived. If the headline estimate
were 9%, as it could be, would the result still be considered
evidence of safety? This highlights the major ﬂaw in these
data, the low-quality assessment of the included studies
highlights the other.
Long-term outcomes after thrombolysis for stroke were
relatively poor. Pooled 90-day mortality was 17%. Thirty-
one to 90-day mortality was 4.4% for patients with
favourable clinical outcomes.4 Therefore the long term
beneﬁts of stroke prevention after CEA in this group areDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.08.012
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http://dx.doi.org/10.1016/j.ejvs.2014.08.018unclear. In addition, secondary endpoints could not be
included in the preceding meta-analysis. A combined
endpoint may have a place in this group of patients as, for
example, the largest randomised trial of thrombolysis to
date had a 2% 7-day incidence of myocardial infarction.3
It is unclear how many units currently offer urgent CEA
after thrombolysis for stroke. Improving stroke services,
guidelines for TIA,2 and emerging evidence for hyperacute
CEA,5 are, however, guiding us inexorably towards the
practice. Randomised trial aside, a close eye must be kept
on registry and trial data for these patients to make sure
they are actually deriving beneﬁt, especially in the long
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